AYURCANN HOLDINGS CORP
Commented by Carsten Mainitz on January 18th, 2022 | 13:07 CET
Ayurcann, Novavax, Covestro - The stragglers are coming!
Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.
Read
Commented by Stefan Feulner on January 12th, 2022 | 12:54 CET
Tilray, Ayurcann, Aurora Cannabis - When will the boom 2.0 come?
About five years ago, the boom of cannabis stocks started. Companies like Aurora Cannabis, Canopy Growth and Tilray were able to multiply within a few months. However, the boom was followed by a quick end on the stock market. With corrections of 90% in some cases, the exaggerations were harshly corrected. However, the cannabis market is still in a strong growth phase. The legalization in many countries and the cannabis 3.0 wave promise the companies enormous growth leaps in the next few years. Thus, the steep rise seen at the time could be repeated, at least to some extent.
Read
Commented by Stefan Feulner on December 28th, 2021 | 07:10 CET
Upcoming hydrogen and cannabis boom - Nel ASA, Ayurcann, Canopy Growth
These two completely different sectors have one thing in common. After both cannabis stocks and hydrogen sector companies multiplied in the past, a significant correction set in during the stock market year soon ending. This correction is likely to continue into the new year 2022. In the long term, however, there are outstanding opportunities both for cannabis, through legalization in various European countries, and for hydrogen, urgently needed for the energy transition. It is time to position yourself.
Read
Commented by Armin Schulz on December 20th, 2021 | 13:56 CET
Alibaba, Ayurcann, Rock Tech Lithium - Portfolio boosters for 2022
The stock market year 2021 is slowly coming to an end, and many investors have cleaned up their portfolios. The question now is, which trends and stocks will ignite in the coming year! The Corona pandemic has come back into focus with the Omicron variant. So this vexed topic will continue to occupy us in the coming year. Profiteers from this are e-commerce companies like Alibaba. With the new traffic light government, the legalization of cannabis is being tackled. Efforts are increasing worldwide to make the consumption of hemp no longer a criminal offense. Well-positioned in this area is Ayurcann. An exciting third market is lithium, which is essential for the production of electric vehicles. Rock Tech Lithium is excellently positioned in this area.
Read
Commented by Fabian Lorenz on December 14th, 2021 | 12:40 CET
BioNTech, Bayer, Ayurcann: From vaccination records to cannabis
The COVID-19 pandemic is dominating the headlines. There is no end in sight to the pandemic. The shares of BioNTech are benefiting from this. The Mainz-based Company has developed the most successful vaccine to date. The blockbuster is likely to remain in demand and generate billions in revenue for BioNTech. Thus, Berenberg sees a price target of USD 400. Health Minister Karl Lauterbach referred to a necessary vaccination rate of over 90% in the ARD program "Anne Will". BioNTech is currently expanding its production capacity. Just like Ayurcann. Because the legalization of cannabis opens the door to a billion-dollar market for the Canadian Company. Bayer also made headlines yesterday - the US Supreme Court is taking a closer look at the glyphosate dispute. That is new food for the gamblers. They have the Bayer share firmly in their grip.
Read
Commented by André Will-Laudien on December 10th, 2021 | 12:54 CET
Daimler, Daimler Trucks, Ayurcann, TUI: Great yield gifts in the Advent season!
The so-called quiet time before Christmas is often associated with cozy warmth, gingerbread and mulled wine. At the stock exchange, the books of the large investors close and private investors optimize their capital gains tax by the realization of pending losses. Because from a pure tax point of view, losses from private sales transactions can be set off against profits; only the annual residual profit then has to be taxed. As a result, the autumn stock markets are often more stormy than many people think, and there is less of a sense of "quiet time," according to Christian beliefs. We pick out a few pieces of gingerbread!
Read
Commented by Stefan Feulner on December 2nd, 2021 | 11:02 CET
Bayer, Ayurcann, JinkoSolar - Excellent prospects
"Release the hemp!" cult presenter Stefan Raab called for the legalization of cannabis years ago in a song he produced himself. But not Jamaica, but the traffic light coalition with SPD, FDP and the Greens caused jubilation in the various communities. The release of the drug opens up great opportunities for young companies as well as investors. In contrast to Germany, other countries have already made more progress. Currently, the cannabis sector is in correction mode on the stock market, but the long-term prospects are excellent.
Read
Commented by Nico Popp on November 23rd, 2021 | 11:19 CET
Bayer, Ayurcann Holdings, Valneva: Three shares, three decisions
The pandemic is dominating the headlines again. For months, investors and the economy believed that lockdowns would never happen again - after all, we had the vaccine. But now Saxony and Bavaria are back on lockdown course. The laws of mathematics suggest that soon other German states will also have to tighten the reins - with all the negative consequences. Shares in the healthcare sector receive special attention in such market phases. We present three representatives.
Read
Commented by André Will-Laudien on November 3rd, 2021 | 13:26 CET
CureVac, Ayurcann, Novavax, NanoRepro: Things are going through the roof here!
Healing and well-being are the focus of many biotech and pharmaceutical companies. In many cases, long research is carried out in order to get corresponding active substances on the way. After many clinical test series, the laborious approval process with the corresponding health authorities then begins. Some companies have provided themselves with good growth capital thanks to the high liquidity on the stock markets and are at the cutting edge with their products. We take a closer look at the industry.
Read
Commented by Stefan Feulner on October 26th, 2021 | 11:37 CEST
Tilray, Ayurcann, Aurora Cannabis, Canopy Growth - Sow first, then reap
After the hype around cannabis companies like Aurora Cannabis, Tilray and Canopy Growth in 2018, consolidation followed, and it continues. But the industry is moving mightily. Smaller companies disappeared from the price list, while big players expanded their market power through mergers and acquisitions for the next few years. The cannabis industry is predicted to grow tremendously in the future. The fantasy is fueled by government legalization plans in several states, including Germany.
Read